论文部分内容阅读
The aim of this study was to collect the evidence on the performance of 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG) Positron Emission Tomography/Computed Tomography (PET/CT) in terms of detection rate (DR) and diagnostic accuracy in identifying hematogenous metastases in patients with differentiated thyroid cancer and compare its performance with that of other imaging techniques. A comprehensive PubMed/MEDLINE database research was carried out to retrieve studies documenting the performance of 18F-FDG PET/CT in depicting hematogenous metastases in patients with differentiated thyroid cancer. Statistical analysis was performed on a per-patient and per-lesion basis. The literature search yielded 15 articles to be included in the systematic review. 18F-FDG PET/CT showed a pooled DR of 85.08％ on a per-patient analysis and 89.70％ on a per-lesion analysis. For bone lesions, a high DR (81.78％) was found for 18F-FDG PET/CT. For the sub-group analysis of lung lesions, pooled DR was 92.77％ for 18F-FDG PET/CT, 95.02％ for CT, and 64.93％ for magnetic resonance imaging (MRI). On a per-patient analysis, 18F-FDG PET/CT demonstrated a pooled sensitivity (SS) of 87.3％ [95％ confidence interval (CI): 77.3％-94％] and a pooled specificity (SP) of 95.6％ (95％CI: 87.6-99.1). On a per-lesion analysis (328 metastases), PET/CT showed a pooled SS and SP of 86.3％ (95％CI: 73.5％-93.5％) and 93.4％ (95％CI: 71.7％-98.8％) in the detection of hematogenous metastases. The presented systematic review and meta-analysis favor the use of 18F-FDG PET/CT in the detection of hematogenous metastases in patients with differentiated thyroid cancer. The limited literature warrants further studies to confirm our findings.